800
Participants
Start Date
November 24, 2021
Primary Completion Date
November 24, 2025
Study Completion Date
November 24, 2025
Nirsevimab
Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
Placebo
Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
Research Site, Linfen
Research Site, Tangshan
Research Site, Beijing
Research Site, Tonghua
Research Site, Nanjing
Research Site, Wuxi
Research Site, Suzhou
Research Site, Tianjin
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Shaoxing
Research Site, Jiaxing
Research Site, Ningbo
Research Site, Wenzhou
Research Site, Changsha
Research Site, Changsha
Research Site, Changde
Research Site, Zhengzhou
Research Site, Xinxiang
Research Site, Sanmenxia
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Shantou
Research Site, Shenzhen
Research Site, Zhongshan
Research Site, Sanya
Research Site, Chengdu
Research Site, Chengdu
Research Site, Kunming
Research Site, Langfang
Research Site, Linfen
Lead Sponsor
IQVIA RDS Inc.
INDUSTRY
AstraZeneca
INDUSTRY